Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

A Phase III trial for an extended-release subcutaneously administered version of the antipsychotic risperidone was positive in patients with schizophrenia.

Subcutaneous injection
Teva hopes to bring a subcutaneous risperidone to market • Source: Shutterstock

Teva Pharmaceutical Industries Ltd., which has been in recovery mode for several years, could have a near-term commercial opportunity with an extended-release, subcutaneously administered formula of the antipsychotic risperidone. A Phase III clinical trial evaluating the efficacy of TV-46000 as a treatment for schizophrenia was positive, the company announced on 7 January.

Only top-line data were released, but the subcutaneous version of a long-acting form of risperidone demonstrated a delay in time...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D